Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Remus Pharmaceuticals Ltd
Your Vote -
Buy
66.67%
Hold
0.00%
Sell
33.33%
66.67%
3 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Remus Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Remus Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Remus Pharmaceutic has declared 5% Final dividend for the financial year March 2025
-
Remus Pharmaceutic - Copy of Newspaper Publication
-
Remus Pharmaceutic - Record Date
-
Remus Pharmaceutic - Shareholders meeting
-
Remus Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Remus Pharmaceutic - Outcome of Board Meeting
-
Remus Pharmaceutic - Investor Presentation
-
Remus Pharmaceutic - Press Release
-
Remus Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Remus Pharmaceutic - General Updates
-
Remus Pharmaceutic - Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
-
Remus Pharmaceutic - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Remus Pharmaceutic has submitted to BSE the Shareholding Pattern for the Period Ended July 07, 2025
-
Remus Pharmaceutic - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Remus Pharmaceutic - Alteration Of Capital and Fund Raising-XBRL
-
Remus Pharmaceutic - Allotment of Securities
-
Remus Pharmaceutic - Outcome of Board Meeting
-
Remus Pharmaceutic - Disclosure under SEBI Takeover Regulations
-
Remus Pharmaceutic - Record Date
-
Remus Pharmaceutic - Shareholders meeting
-
Remus Pharmaceutic - Shareholders meeting
Key fundamentals
Evaluate the intrinsic value of Remus Pharmaceuticals Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 244.36 | 83.5026 | 27.0783 | 6.6235 | 3.325 |
| Liabilities | 244.36 | 83.5026 | 27.0783 | 6.6235 | 3.325 |
| Equity | 5.89 | 1.473 | 1.085 | 1 | 0.01 |
| Gross Profit | 25.98 | 20.0439 | 10.5464 | 4.0707 | 0.7618 |
| Net Profit | 19.9 | 16.8197 | 8.5028 | 3.3857 | 1.0258 |
| Cash From Operating Activities | 15.59 | 2.4263 | 5.3129 | 5.0378 | 2.8379 |
| NPM(%) | 25.13 | 26.48 | 18.88 | 13.69 | 5.56 |
| Revenue | 79.16 | 63.4965 | 45.0273 | 24.7171 | 18.4181 |
| Expenses | 53.18 | 43.4526 | 34.4809 | 20.6464 | 17.6563 |
| ROE(%) | 7.77 | 6.57 | 3.32 | 1.32 | 0.4 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 02 May 2024 | 4 | 40 | 0 | 6911.75 |
| 27 Oct 2023 | 2 | 20 | 0 | 5537.5 |
Peers
Other companies within the same industry or sector that are comparable to Remus Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 802.05 | -1.07 | 72.72 | 0.00 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 120.78 | 0.24 | 389.61 | 0.00 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 12.11 | -1.06 | 403.67 | 0.00 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 824.95 | -1.29 | 0.00 | 0.00 | -604.77 | 0.00 |
Company Info
The Company was originally incorporated as `Remus Pharmaceuticals Private Limited' as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, the Company was converted from a private limited company to public limited company and consequently, the name of the Company was changed to "Remus Pharmaceuticals Limited", and a fresh certificate of incorporation dated January 06, 2023 was issued to the Company by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company is U24232GJ2015PLC084536. MAJOR EVENTS : 2015 - The Company was incorporated as a private limited company under the name "Remus Pharmaceuticals Private Ltd - Conversion of the company from Private Limited to Public Limited Company - Initiation of finished formulation exports and marketing 2019 -Collaboration & partnership with multinational pharmaceuticals 2022 -Initiation of strategic presence in a few key markets 2024 -The Company has issued Bonus Shares in the Ratio of 3:1.
The Company was originally incorporated as `Remus Pharmaceuticals Private Limited' as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, the Company was converted from a private limited company to public limited company and consequently, the name of the Company was changed to "Remus Pharmaceuticals Limited", and a fresh certificate of incorporation dated January 06, 2023 was issued to the Company by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company is U24232GJ2015PLC084536. MAJOR EVENTS : 2015 - The Company was incorporated as a private limited company under the name "Remus Pharmaceuticals Private Ltd - Conversion of the company from Private Limited to Public Limited Company - Initiation of finished formulation exports and marketing 2019 -Collaboration & partnership with multinational pharmaceuticals 2022 -Initiation of strategic presence in a few key markets 2024 -The Company has issued Bonus Shares in the Ratio of 3:1.
Read More
Parent Organisation
Remus Pharmaceuticals Ltd.
Founded
21/09/2015
Managing Director
Mr.Arpit Deepakkumar Shah
NSE Symbol
REMUSSM
FAQ
The current price of Remus Pharmaceuticals Ltd is
The 52-week high for Remus Pharmaceuticals Ltd is
The market capitalization of Remus Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Remus Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Remus Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Remus Pharmaceuticals Ltd shares.
The CEO of Remus Pharmaceuticals Ltd is Mr.Arpit Deepakkumar Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
